Alnylam Pharmaceuticals, Inc. (ALNY) Financial Statements
Historical financial data — 42 statements covering FY2018–FY2025
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulatio...
Alnylam Pharmaceuticals, Inc.'s revenue increased 65.2% year over year, from $2.25B to $3.71B.
Net income increased 212.8% over the same period, from $-278.2M to $313.7M.
Over the 7-year period from FY2018 to FY2025, revenue grew by 4858% in total.
Operating cash flow grew 6405.1% to $524.1M.
Alnylam Pharmaceuticals, Inc. maintains a moderate net profit margin of 8.4%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Equity |
|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $500.9M-24.1% | $-111.6M | $418.9M | $-76.9M | $43.7M | $4.21B | $32.4M |
| Q4 FY2024 | $593.2M+18.4% | $-83.8M | $490.5M | $-105.2M | $-94.7M | $4.24B | $67.1M |
| Q1 FY2025 | $594.2M+0.2% | $-57.5M | $524.0M | $18.1M | $-118.3M | $4.21B | $115.4M |
| Q2 FY2025 | $773.7M+30.2% | $-66.3M | $631.7M | $-16.2M | $153.7M | $4.57B | $250.6M |
| Q3 FY2025 | $1.25B+61.4% | $251.1M | $1.05B | $368.0M | $325.1M | $4.85B | $233.9M |
| Q4 FY2025 | $1.10B-12.2% | $186.4M | $829.3M | $131.7M | $163.6M | $4.97B | $789.2M |
| Q1 FY2026 | $1.17B+6.4% | $206.0M | $959.7M | $268.6M | $70.5M | N/A | N/A |
| Q2 FY2026 | $1.29B+10.6% | $164.5M | $992.7M | $231.4M | $326.7M | N/A | N/A |
Balance Sheet Summary (FY2025)
Alnylam Pharmaceuticals, Inc. (ALNY) Financial Statements & Revenue History
Alnylam Pharmaceuticals, Inc. (ALNY) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $231.83 with a market capitalization of $31. This page provides 42 historical financial statements for Alnylam Pharmaceuticals, Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Alnylam Pharmaceuticals, Inc. reported revenue of $3.7 billion, representing 65.2% year-over-year growth. The net profit margin of 8.4% indicates moderate profitability..
ALNY Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Alnylam Pharmaceuticals, Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether ALNY is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track ALNY's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Alnylam Pharmaceuticals, Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of ALNY's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use ALNY Financial Data
Investors use Alnylam Pharmaceuticals, Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare ALNY's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how ALNY's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View ALNY's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Alnylam Pharmaceuticals, Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.ALNY trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.